CGRP RECEPTOR ANTAGONISTS
Disclosed is a thiazolidine compound of formula (I) where the substituents are as disclosed in the specification. Example of compound of formula (I) include: 1-(1-(2-(4-Oxo-2-phenyl-3-((pyridin-4-yl)methyl)thiazolidin-5-yl)acetyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one; 3,4-Dihydro-3-(1-(2-(3-...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Disclosed is a thiazolidine compound of formula (I) where the substituents are as disclosed in the specification. Example of compound of formula (I) include: 1-(1-(2-(4-Oxo-2-phenyl-3-((pyridin-4-yl)methyl)thiazolidin-5-yl)acetyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one; 3,4-Dihydro-3-(1-(2-(3-methyl-4-oxo-2-phenylthiazolidin-5-yl)acetyl)piperidin-4-yl)quinazolin-2(1H)-one and 3-(1-(2-(3-Isopentyl-4-oxo-2-phenylthiazolidin-5-yl)propanoyl)piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one. Also disclosed is the pharmaceutical composition comprising a compound of formula (I) and the use of a compound of formula9I) in the manufacture of a medicament for treating or preventing headache; migraine; cluster headache; chronic tension type headache; pain; chronic pain; neurogenic inflammation and inflammatory pain; neuropathic pain; eye pain; tooth pain; diabetes; non-insulin dependent diabetes mellitus; vascular disorders; inflammation; arthritis; bronchial hyperactivity, asthma; shock; sepsis; opiate withdrawal syndrome; morphine tolerance; hot flashes in men and women; allergic dermatitis; encephalitis; brain trauma; epilepsy; neurodegenerative diseases; skin diseases; neurogenic cutaneous redness, skin rosaceous and erythema; tinnitus; inflammatory bowel disease, irritable bowel syndrome, or cystitis. |
---|